15 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
with respect to such product candidate. The obe-cel Regenerative Medicine Advanced Therapy (“RMAT”) designation was submitted to FDA in February 2022 … for the development and review of certain regenerative medicine therapies. To receive RMAT designation, a regenerative medicine product candidate must be intended
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
26 Jan 24
Regulation FD Disclosure
1:02pm
half of 2024. Obe-cel has been granted Orphan Drug Designation by the FDA, Orphan Medical Product Designation by the EMA, Regenerative Medicine
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
27 Nov 23
Regulation FD Disclosure
7:07am
Orphan Drug Designation by the FDA, Orphan Medical Product Designation by the EMA, Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
June 30, 2022. “Autolus has had a successful second quarter, with progress made across all fronts. We were awarded Regenerative Medicine Advanced
6-K
EX-99.2
AUTL
Autolus Therapeutics plc
5 May 22
Index to Condensed Consolidated Financial Statements
12:00am
and Drug Administration, or the FDA, for B-cell acute lymphoblastic leukemia, or B-ALL.
In April 2022, the FDA granted Regenerative Medicine Advanced
6-K
EX-1
dg7e joauuyp4
30 Jun 21
Annual Report and Accounts
6:05am
6-K
EX-1
xbe90wlr
26 May 20
Current report (foreign)
4:31pm
424B4
ewhxwq5
11 Apr 19
Prospectus supplement with pricing info
4:10pm
F-1
u2wi6flmrre ei50z1
8 Apr 19
Registration statement (foreign)
4:34pm
6-K
EX-1
urskss1 wk3qk
15 Mar 19
Annual Report and Accounts
5:26pm
DRS
bhn3s9wm
23 Nov 18
Draft registration statement
12:00am
20-F
l8teioe
23 Nov 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next